MENVEO
Meningococcal A, C, W-135, Y oligosaccharide conjugate · Meningococcal (Men-C, ACYW, Men-B)
Health Canada DIN 02347393. Check the product and formulation on your record before using a schedule.
Plan doses for this product →At a glance
- Brand
- MENVEO
- DIN
02347393- Vaccine
- Meningococcal A, C, W-135, Y oligosaccharide conjugate
- Presentation
- 0.5 mL · powder + solution (two vials) · intramuscular · 2 months and older
- Live vaccine
- No
Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with the Care365 clinical team or doctor.
Official product information
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
Read product monograph (PDF) ↗
A listed product may not be stocked or publicly funded.
Dose schedules involving this product
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination.
| Schedule | Doses | Who it applies to |
|---|---|---|
| Meningococcal ACYW — toddler dose at 12 to 23 months One dose of quadrivalent (Men-C-ACYW) conjugate vaccine at 12 to 23 months. | 1 dose | NACI (May 2026): all children 12 to 23 months of age should receive one dose of quadrivalent meningococcal conjugate (Men-C-ACYW) vaccine, replacing the Men-C-C toddler dose. A child who already had Men-C-C at 12 to 23 months is not revaccinated. MENQUADFI is authorized from 12 months, NIMENRIX from 6 weeks, MENVEO from 2 months. |
| Meningococcal ACYW — routine adolescent or adult, one dose One dose of Men-C-ACYW conjugate vaccine, routinely given at about 12 years of age. | 1 dose | Routine single adolescent dose regardless of infant or toddler history; also for adults with travel, occupational or outbreak indications. |
| Meningococcal ACYW — high-risk conditions, two doses Two doses 8 weeks apart for asplenia, complement deficiency, HIV and other high-risk conditions. | 2 doses | For people 12 months and older with no spleen or a spleen that does not work, complement or properdin deficiency (including eculizumab or ravulizumab treatment), HIV, or other high-risk conditions. Two doses at least 8 weeks apart (4 weeks if accelerated). A booster every 5 years while risk continues (every 3 years if first immunized under 7 years of age). |
Pregnancy and breastfeeding
Family guidance on pregnancy: Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
Family guidance on breastfeeding: Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
This guidance applies to the vaccine family. Confirm this product's details in the monograph and with your clinician. Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026.
Sources and next steps
- NACI rapid response: quadrivalent conjugate meningococcal vaccines in children under 2 years of age — Published May 2026
- Meningococcal vaccines: Canadian Immunization Guide — Chapter revised May 2015 · partial update March 2025
- Health Canada product record
General information only. A suggested date is not an appointment or a prescription; the Care365 clinical team or doctor confirms what you need. Clinical rules reviewed on 2026-09-27.
Review with Care365